The significance of intertumor and intratumor heterogeneity in liver cancer

[1]  S. Friedman,et al.  Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. , 2017, Gastroenterology.

[2]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[3]  D. Weitz,et al.  An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma , 2017, Proceedings of the National Academy of Sciences.

[4]  Jessica M. Rusert,et al.  Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity , 2017, Nature.

[5]  A. Veronese,et al.  Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers , 2016, Gut.

[6]  Ruibin Xi,et al.  Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. , 2017, Gastroenterology.

[7]  P. Zhu,et al.  LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells , 2016, Nature Communications.

[8]  L. Fu,et al.  [Genetic heterogeneity of breast cancer]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[9]  T. Golub,et al.  Genetic interrogation of circulating multiple myeloma cells at single-cell resolution , 2016, Science Translational Medicine.

[10]  William Pao,et al.  AACR Cancer Progress Report 2016 , 2016, Clinical Cancer Research.

[11]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[12]  Hazen P Babcock,et al.  High-throughput single-cell gene-expression profiling with multiplexed error-robust fluorescence in situ hybridization , 2016, Proceedings of the National Academy of Sciences.

[13]  P. Zhu,et al.  lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal , 2016, Nature Structural &Molecular Biology.

[14]  Xiao-Jun Ma,et al.  Fully Automated RNAscope In Situ Hybridization Assays for Formalin‐Fixed Paraffin‐Embedded Cells and Tissues , 2016, Journal of cellular biochemistry.

[15]  J. Lee,et al.  Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma , 2016, Oncotarget.

[16]  Zemin Zhang,et al.  Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[17]  W. Koh,et al.  Single-cell genome sequencing: current state of the science , 2016, Nature Reviews Genetics.

[18]  Lu Wen,et al.  Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas , 2016, Cell Research.

[19]  Ruibin Xi,et al.  Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity , 2015, Oncotarget.

[20]  J. Prieto,et al.  Immunological landscape and immunotherapy of hepatocellular carcinoma , 2015, Nature Reviews Gastroenterology &Hepatology.

[21]  Xuemei Lu,et al.  Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution , 2015, Proceedings of the National Academy of Sciences.

[22]  X. Wang,et al.  The search for precision models clinically relevant to human liver cancer. , 2015, Hepatic oncology.

[23]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[24]  Sridhar Ramaswamy,et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.

[25]  Hiromi Nakamura,et al.  Genomic spectra of biliary tract cancer , 2015, Nature Genetics.

[26]  Hao Chen,et al.  Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis , 2015, Cellular Physiology and Biochemistry.

[27]  Franziska Michor,et al.  In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer , 2015, Nature Genetics.

[28]  H. Weir,et al.  The past, present, and future of cancer incidence in the United States: 1975 through 2020 , 2015, Cancer.

[29]  X. Zhuang,et al.  Spatially resolved, highly multiplexed RNA profiling in single cells , 2015, Science.

[30]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[31]  Runsheng Chen,et al.  The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. , 2015, Cell stem cell.

[32]  B. Lim,et al.  Non‐invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients , 2015, Molecular oncology.

[33]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[34]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[35]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[36]  Hongxin Ma,et al.  Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages , 2015, Gut.

[37]  Martin C. Müller,et al.  Implications of BCR-ABL 1 kinase domain-mediated resistance in chronic myeloid leukemia , 2015 .

[38]  N. Lin,et al.  Hypoxia-induced secretion of platelet-derived growth factor-BB by hepatocellular carcinoma cells increases activated hepatic stellate cell proliferation, migration and expression of vascular endothelial growth factor-A. , 2015, Molecular medicine reports.

[39]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[40]  Yang Zhang,et al.  microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma , 2015, Molecular Cancer.

[41]  X. Wang,et al.  The biological and clinical challenge of liver cancer heterogeneity. , 2014, Hepatic oncology.

[42]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[43]  T. Greten,et al.  Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions , 2014, Hepatology.

[44]  Diverse modes of genomic alteration in hepatocellular carcinoma , 2014, Genome Biology.

[45]  Daniel Öhlund,et al.  Fibroblast heterogeneity in the cancer wound , 2014, The Journal of experimental medicine.

[46]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[47]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[48]  E. Gostick,et al.  Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma , 2014, Hepatology.

[49]  S. Nelson,et al.  Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.

[50]  Martin C. Müller,et al.  Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. , 2014, Leukemia research.

[51]  Peiyuan Li,et al.  Netrin-1 Induces Epithelial–Mesenchymal Transition and Promotes Hepatocellular Carcinoma Invasiveness , 2014, Digestive Diseases and Sciences.

[52]  Elaine R Mardis,et al.  AACR Cancer Progress Report 2013 , 2013, Clinical Cancer Research.

[53]  J. Zucman‐Rossi,et al.  Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.

[54]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[55]  H. Gevensleben,et al.  Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. , 2013, Journal of hepatology.

[56]  E. Shapiro,et al.  Single-cell sequencing-based technologies will revolutionize whole-organism science , 2013, Nature Reviews Genetics.

[57]  S. Sleijfer,et al.  KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue , 2013, International journal of cancer.

[58]  Peter Ulz,et al.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. , 2013, Cancer research.

[59]  Rameen Beroukhim,et al.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.

[60]  B. Pulendran,et al.  Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid , 2013, The Journal of Immunology.

[61]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[62]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[63]  Hyun Goo Woo,et al.  Transcriptomic profiling reveals hepatic stem‐like gene signatures and interplay of miR‐200c and epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma , 2012, Hepatology.

[64]  Xiaochu Yan,et al.  Nanog regulates self‐renewal of cancer stem cells through the insulin‐like growth factor pathway in human hepatocellular carcinoma , 2012, Hepatology.

[65]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[66]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[67]  V. Mazzaferro,et al.  Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. , 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[69]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[70]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[71]  M. Takamura,et al.  Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. , 2012, Journal of hepatology.

[72]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[73]  Arthur Liberzon,et al.  Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. , 2011, Gastroenterology.

[74]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[75]  Jessica Zucman-Rossi,et al.  Molecular classification of hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[76]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[77]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[78]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[80]  M. Manns,et al.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.

[81]  Minshan Chen,et al.  Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[82]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[83]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[84]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[85]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[86]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[87]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[88]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[89]  C. Preudhomme,et al.  A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. , 2003, The New England journal of medicine.

[90]  X. Wang,et al.  Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning , 2003, Nature Medicine.

[91]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[92]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[93]  H. Moch,et al.  Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies , 2001, The Journal of pathology.

[94]  S. Hirohashi,et al.  Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma , 2000, Hepatology.

[95]  N. Lemoine,et al.  Evolution of genetic abnormalities in hepatocellular carcinomas demonstrated by DNA fingerprinting , 1999, The Journal of pathology.

[96]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[97]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[98]  D. Adams,et al.  Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. , 1998, Journal of immunology.

[99]  B. le Bail,et al.  Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: Evidence for a role of hepatocyte growth factor , 1997, Hepatology.

[100]  S. Hirohashi,et al.  The E‐cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas , 1997, International journal of cancer.

[101]  T. Nakajima,et al.  Cytogenetic analyses of hepatocellular carcinoma by in situ hybridization with a chromosome‐specific DNA probe , 1996, Cancer.

[102]  S. Tanaka,et al.  Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. , 1993, Cancer research.

[103]  G. Heppner,et al.  Genetic heterogeneity in breast cancer. , 1992, Journal of the National Cancer Institute.

[104]  H. Hsu,et al.  Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules , 1991, Hepatology.

[105]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[106]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[107]  M. Kojiro,et al.  Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. , 2008, Liver.

[108]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.